(Reuters) - Last month, AstraZeneca agreed to buy MedImmune in its biggest transaction since the creation of the Anglo-Swedish drugs group in 1999. The all-cash deal aims to boost AstraZeneca's depleted drug portfolio by moving deeper into biotech medicine and taking a first step into vaccines.
MedImmune is one of the largest independent U.S. biotech companies and is best known for the nasal spray flu vaccine FluMist. The Maryland-based company also has two other marketed products, Synagis for infectious respiratory disease and Ethyol for reducing chemotherapy side effects.
Read more at Reuters.com Government Filings News
MedImmune is one of the largest independent U.S. biotech companies and is best known for the nasal spray flu vaccine FluMist. The Maryland-based company also has two other marketed products, Synagis for infectious respiratory disease and Ethyol for reducing chemotherapy side effects.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment